- Home
- IIIN vs ATXS Comparison
IIIN vs ATXS Comparison
Compare IIIN & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIN
- ATXS
- Stock Information
- Founded
- IIIN 1953
- ATXS 2008
- Country
- IIIN United States
- ATXS United States
- Employees
- IIIN N/A
- ATXS N/A
- Industry
- IIIN Steel/Iron Ore
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- IIIN Industrials
- ATXS Health Care
- Exchange
- IIIN Nasdaq
- ATXS Nasdaq
- Market Cap
- IIIN 606.6M
- ATXS 676.1M
- IPO Year
- IIIN N/A
- ATXS 2015
- Fundamental
- Price
- IIIN $31.71
- ATXS $12.63
- Analyst Decision
- IIIN
- ATXS Buy
- Analyst Count
- IIIN 0
- ATXS 7
- Target Price
- IIIN N/A
- ATXS $30.00
- AVG Volume (30 Days)
- IIIN 169.7K
- ATXS 4.3M
- Earning Date
- IIIN 10-16-2025
- ATXS 11-12-2025
- Dividend Yield
- IIIN 3.53%
- ATXS N/A
- EPS Growth
- IIIN 112.14
- ATXS N/A
- EPS
- IIIN 2.10
- ATXS N/A
- Revenue
- IIIN $647,706,000.00
- ATXS N/A
- Revenue This Year
- IIIN $14.97
- ATXS N/A
- Revenue Next Year
- IIIN $7.00
- ATXS N/A
- P/E Ratio
- IIIN $15.09
- ATXS N/A
- Revenue Growth
- IIIN 22.39
- ATXS N/A
- 52 Week Low
- IIIN $22.49
- ATXS $3.56
- 52 Week High
- IIIN $41.64
- ATXS $12.72
- Technical
- Relative Strength Index (RSI)
- IIIN 38.82
- ATXS 73.44
- Support Level
- IIIN $31.00
- ATXS $12.20
- Resistance Level
- IIIN $32.09
- ATXS $12.65
- Average True Range (ATR)
- IIIN 0.87
- ATXS 0.23
- MACD
- IIIN 0.25
- ATXS -0.15
- Stochastic Oscillator
- IIIN 77.40
- ATXS 83.19
About IIIN Insteel Industries Inc.
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.